Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis.

Conklin LS, Merkel PA, Pachman LM, Parikh H, Tawalbeh S, Damsker JM, Cuthbertson DD, Morgan GA, Monach PA, Hathout Y, Nagaraju K, van den Anker J, McAlear CA, Hoffman EP.

Steroids. 2018 Dec;140:159-166. doi: 10.1016/j.steroids.2018.10.008. Epub 2018 Oct 21.

2.

Is Mastery Motivation a Mediator of Relations between Maternal Teaching Behavior and Developmental Abilities in Children with Global Developmental Delay?

Wang PJ, Chen LC, Liao HF, Tu YK, Lu L, Morgan GA.

Phys Occup Ther Pediatr. 2019;39(3):292-309. doi: 10.1080/01942638.2018.1505800. Epub 2018 Sep 28.

PMID:
30265825
3.

Decreased CD3-CD16+CD56+ natural killer cell counts in children with orbital myositis: a clue to disease activity.

Briones MR, Morgan GA, Amoruso MC, Rahmani B, Ryan ME, Pachman LM.

RMD Open. 2017 Jul 11;3(1):e000385. doi: 10.1136/rmdopen-2016-000385. eCollection 2017.

4.

Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study.

Xu D, Kacha-Ochana A, Morgan GA, Huang CC, Pachman LM.

Pediatr Rheumatol Online J. 2017 May 17;15(1):42. doi: 10.1186/s12969-017-0171-3.

5.

Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study.

Mendelsohn RB, Winawer SJ, Jammula A, Mills G, Jordan P, O'Brien MJ, Close GM, Dorfman M, Church TR, Mandelson MT, Allen J, Feld A, Kauff ND, Morgan GA, Kumar JMR, Serrano V, Bayuga-Miller S, Fischer SE, Kuk D, Zauber AG.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1469-1470. doi: 10.1016/j.cgh.2017.04.014. Epub 2017 Apr 15. No abstract available.

6.

Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography.

Ibarra M, Rigsby C, Morgan GA, Sammet CL, Huang CC, Xu D, Targoff IN, Pachman LM.

Pediatr Rheumatol Online J. 2016 Nov 29;14(1):64.

7.

MicroRNA-10a Regulation of Proinflammatory Mediators: An Important Component of Untreated Juvenile Dermatomyositis.

Xu D, Huang CC, Kachaochana A, Morgan GA, Bonaldo MF, Soares MB, Costa F, Sarwark J, Sredni ST, Pachman LM.

J Rheumatol. 2016 Jan;43(1):161-8. doi: 10.3899/jrheum.141474. Epub 2015 Dec 1.

PMID:
26628598
8.

Do maternal interactive behaviors correlate with developmental outcomes and mastery motivation in toddlers with and without motor delay?

Wang PJ, Morgan GA, Hwang AW, Chen LC, Liao HF.

Phys Ther. 2014 Dec;94(12):1744-54. doi: 10.2522/ptj.20130560. Epub 2014 Aug 21.

PMID:
25147184
9.

Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis.

QuiƱones R, Morgan GA, Amoruso M, Field R, Huang CC, Pachman LM.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1697-701. doi: 10.1002/acr.22041.

10.

3D reconstruction of the source and scale of buried young flood channels on Mars.

Morgan GA, Campbell BA, Carter LM, Plaut JJ, Phillips RJ.

Science. 2013 May 3;340(6132):607-10. doi: 10.1126/science.1234787. Epub 2013 Mar 7.

11.

Individualized behavioral assessments and maternal ratings of mastery motivation in mental age-matched toddlers with and without motor delay.

Wang PJ, Morgan GA, Hwang AW, Liao HF.

Phys Ther. 2013 Jan;93(1):79-87. doi: 10.2522/ptj.20120068. Epub 2012 Sep 13.

PMID:
22976444
12.

Methylation alterations of WT1 and homeobox genes in inflamed muscle biopsy samples from patients with untreated juvenile dermatomyositis suggest self-renewal capacity.

Wang M, Xie H, Shrestha S, Sredni S, Morgan GA, Pachman LM.

Arthritis Rheum. 2012 Oct;64(10):3478-85. doi: 10.1002/art.34573.

13.

Maternal parenting stress and mothers' reports of their infants' mastery motivation.

Sparks TA, Hunter SK, Backman TL, Morgan GA, Ross RG.

Infant Behav Dev. 2012 Feb;35(1):167-73. doi: 10.1016/j.infbeh.2011.07.002. Epub 2011 Sep 3.

14.

Familial aggregation of autoimmune disease in juvenile dermatomyositis.

Niewold TB, Wu SC, Smith M, Morgan GA, Pachman LM.

Pediatrics. 2011 May;127(5):e1239-46. doi: 10.1542/peds.2010-3022. Epub 2011 Apr 18.

15.

Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis.

Kim NN, Lio PA, Morgan GA, Jarvis JN, Pachman LM.

Arch Dermatol. 2011 Jul;147(7):831-5. doi: 10.1001/archdermatol.2011.49. Epub 2011 Mar 21.

PMID:
21422326
16.

Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis.

Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM.

J Pediatr. 2010 Oct;157(4):653-7. doi: 10.1016/j.jpeds.2010.04.034.

17.

Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis.

Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM.

Arthritis Care Res (Hoboken). 2010 Oct;62(10):1446-51. doi: 10.1002/acr.20269.

18.

Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis.

Ostrowski RA, Sullivan CL, Seshadri R, Morgan GA, Pachman LM.

Arthritis Rheum. 2010 May;62(5):1533-8. doi: 10.1002/art.27379.

19.

GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

Hennan JK, Swillo RE, Morgan GA, Rossman EI, Kantrowitz J, Butera J, Petersen JS, Gardell SJ, Vlasuk GP.

J Cardiovasc Pharmacol Ther. 2009 Sep;14(3):207-14. doi: 10.1177/1074248409340779.

PMID:
19721133
20.

Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents.

Piatnitski Chekler EL, Butera JA, Di L, Swillo RE, Morgan GA, Rossman EI, Huselton C, Larsen BD, Hennan JK.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4551-4. doi: 10.1016/j.bmcl.2009.07.014. Epub 2009 Jul 9.

PMID:
19616941
21.

Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.

Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM.

Arthritis Rheum. 2009 Jun;60(6):1815-24. doi: 10.1002/art.24555.

22.

The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.

Rossman EI, Liu K, Morgan GA, Swillo RE, Krueger JA, Gardell SJ, Butera J, Gruver M, Kantrowitz J, Feldman HS, Petersen JS, Haugan K, Hennan JK.

J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33. doi: 10.1124/jpet.108.150102. Epub 2009 Feb 27.

PMID:
19252062
23.

Altered microvascular hemodynamics during the induction and perpetuation of chronic gut inflammation.

Harris NR, Whatley JR, Carter PR, Morgan GA, Grisham MB.

Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G750-4. doi: 10.1152/ajpgi.90702.2008. Epub 2009 Feb 12.

24.

Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation.

Butera JA, Larsen BD, Hennan JK, Kerns E, Di L, Alimardanov A, Swillo RE, Morgan GA, Liu K, Wang Q, Rossman EI, Unwalla R, McDonald L, Huselton C, Petersen JS.

J Med Chem. 2009 Feb 26;52(4):908-11. doi: 10.1021/jm801558d.

PMID:
19175320
25.

Ozagrel reverses streptozotocin-induced constriction of arterioles in rat retina.

Lee S, Morgan GA, Harris NR.

Microvasc Res. 2008 Nov;76(3):217-23. doi: 10.1016/j.mvr.2008.07.005. Epub 2008 Jul 31.

26.

Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis.

Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, Vlasuk GP, Gardell SJ, Crandall DL.

J Thromb Haemost. 2008 Sep;6(9):1558-64. doi: 10.1111/j.1538-7836.2008.03063.x. Epub 2008 Jul 4.

27.

Contrasting effects of pseudoephedrine and papaverine in dextran sodium sulfate-induced colitis.

Harris NR, Specian RD, Carter PR, Morgan GA.

Inflamm Bowel Dis. 2008 Mar;14(3):318-23.

PMID:
17941078
28.

Defects of immune regulation in the presenilin-1 mutant knockin mouse.

Morgan GA, Guo Q, Chan SL, Gary DS, Osborne BA, Mattson MP.

Neuromolecular Med. 2007;9(1):35-45.

PMID:
17114823
29.

Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.

Hennan JK, Swillo RE, Morgan GA, Leik CE, Brooks JM, Shaw GD, Schaub RG, Crandall DL, Vlasuk GP.

Thromb Haemost. 2006 Mar;95(3):469-75.

PMID:
16525575
30.

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

Hennan JK, Swillo RE, Morgan GA, Keith JC Jr, Schaub RG, Smith RP, Feldman HS, Haugan K, Kantrowitz J, Wang PJ, Abu-Qare A, Butera J, Larsen BD, Crandall DL.

J Pharmacol Exp Ther. 2006 Apr;317(1):236-43. Epub 2005 Dec 12.

PMID:
16344331
31.

Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.

Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL.

J Pharmacol Exp Ther. 2005 Aug;314(2):710-6. Epub 2005 Apr 28.

PMID:
15860572
32.

The Formation and Stability of Adsorbed Formyl as a Possible Intermediate in Fischer-Tropsch Chemistry on Ruthenium.

Morgan GA Jr, Sorescu DC, Zubkov T, Yates JT Jr.

J Phys Chem B. 2004 Mar 18;108(11):3614-3624. doi: 10.1021/jp0310753.

PMID:
28786676
33.

Measures of clinical significance.

Kraemer HC, Morgan GA, Leech NL, Gliner JA, Vaske JJ, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2003 Dec;42(12):1524-9. No abstract available.

PMID:
14627890
34.

WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation.

Crandall DL, Hennan JK, Elokdah H, Krishnamurthy G, Antrilli TM, Bauer JS, Morgan GA, Swillo RE.

Biochem Biophys Res Commun. 2003 Nov 28;311(4):904-8.

PMID:
14623266
35.

Meta-analysis: formulation and interpretation.

Gliner JA, Morgan GA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2003 Nov;42(11):1376-9. No abstract available.

PMID:
14566176
36.

Selection and use of inferential statistics: a summary.

Morgan GA, Gliner JA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2003 Oct;42(10):1253-7. Review. No abstract available.

PMID:
14560177
37.

Use and interpretation of multiple regression.

Leech NL, Gliner JA, Morgan GA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2003 Jun;42(6):738-40. No abstract available.

PMID:
12921482
38.

Logistic regression and discriminant analysis: use and interpretation.

Morgan GA, Vaske JJ, Gliner JA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2003 Aug;42(8):994-7. No abstract available.

PMID:
12874503
39.

Pretest-posttest comparison group designs: analysis and interpretation.

Gliner JA, Morgan GA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2003 Apr;42(4):500-3. No abstract available.

PMID:
12649639
40.

The role of ICAM-1 as a signal protein for predisposition of ocular surface inflammation.

Stem ME, Gao J, Morgan GA, Brees D, Schwalb TA, Humphreys-Behr M, Smith JA.

Adv Exp Med Biol. 2002;506(Pt B):753-9. No abstract available.

PMID:
12613988
41.

Between-groups factorial designs: analysis and interpretation.

Morgan GA, Gliner JA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2003 Feb;42(2):249-52. No abstract available.

PMID:
12544186
42.

The chi-square test and accompanying effect size indices.

Gliner JA, Morgan GA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2002 Dec;41(12):1510-2. No abstract available.

PMID:
12447039
43.

Basic associational designs: analysis and interpretation.

Gliner JA, Morgan GA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2002 Oct;41(10):1256-8. No abstract available.

PMID:
12364849
44.

Single-factor repeated-measures designs: analysis and interpretation.

Gliner JA, Morgan GA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2002 Aug;41(8):1014-6.

PMID:
12162619
45.

Single-factor between-groups designs: analysis and interpretation.

Gliner JA, Morgan GA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2002 Jun;41(6):742-4. No abstract available.

PMID:
12049450
46.

The acute pain service, a model for outreach critical care.

Morgan GA, Lawler PG.

Anaesthesia. 2002 Apr;57(4):404-5. No abstract available.

47.

Selection of inferential statistics: an overview.

Morgan GA, Gliner JA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2002 Apr;41(4):478-81. Review.

PMID:
11931606
48.

General design classifications.

Morgan GA, Gliner JA, Harmon RJ.

J Am Acad Child Adolesc Psychiatry. 2002 Feb;41(2):226-8.

PMID:
11837414
49.

Ethical issues related to publishing and reviewing.

Morgan GA, Harmon RJ, Gliner JA.

J Am Acad Child Adolesc Psychiatry. 2001 Dec;40(12):1476-8. No abstract available.

PMID:
11765295
50.

Ethical problems and principles in human research.

Morgan GA, Harmon RJ, Gliner JA.

J Am Acad Child Adolesc Psychiatry. 2001 Oct;40(10):1231-3. No abstract available.

PMID:
11589537

Supplemental Content

Loading ...
Support Center